The purpose of this study was to develop a harmonized method to collect, compare and...

Governments around the world are increasingly engaged with the political mandate of innovation, which is...

Society supports drug R&D by granting drug companies patents and other forms of intellectual property...

Prompt and affordable access to essential medicines is a component of almost all domestic and...

Canada's linkage regime for pharmaceuticals, modeled after the originating U.S. Hatch-Waxman regime, was brought in...

Canada’s linkage regime for pharmaceuticals, modeled after the originating U.S. Hatch-Waxman regime, was brought in...

Global drug regulators have long privileged models of therapeutic product development that provide strong intellectual...

Canada’s proposed new drug regime, termed the “Progressive Licensing Framework” (PLF), has received consid-erable attention...

Canada is currently undergoing a transition in its system of public health, including major redefinition...

Global drug development is undergoing a redefinition of the responsibilities of those who develop, regulate,...

In KSR, SCOTUS retooled the standard for obviousness to bring it back in line with...

The allocation of risks and benefits of publicly sponsored biomedical research is becoming increasingly skewed...

There is little question that substantial benefits accrue to society from biomedical research. It is...

The purpose of this article is to gain insight into the relationship between obviousness and...

This article is an analysis of case law pertaining to whether scientific research in the...